Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Phase II Study of Alternating Sunitinib and Temsirolimus
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT01517243
- Locations
- 🇺🇸
University of Vermont, Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- AB Science
- Target Recruit Count
- 44
- Registration Number
- NCT01506336
- Locations
- 🇫🇷
Institute Gustave Roussy (IGR), Villejuif, France
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 14
- Registration Number
- NCT01502228
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 117
- Registration Number
- NCT01499121
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 9
- Registration Number
- NCT01498835
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪University Medical Center Mannheim, Mannheim, Germany
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
- Conditions
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 194
- Registration Number
- NCT01472081
- Locations
- 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Nassau, New York, New York, United States
🇺🇸Blumenthal Cancer Center, Charlotte, North Carolina, United States
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
- Conditions
- Childhood Cerebral Anaplastic AstrocytomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Subependymal Giant Cell AstrocytomaChildhood Cerebral AstrocytomaChildhood Cerebellar Anaplastic AstrocytomaRecurrent Childhood Cerebral AstrocytomaChildhood Mixed Glioma
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT01462695
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital Central California, Madera, California, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
- Conditions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Markus Joerger
- Target Recruit Count
- 54
- Registration Number
- NCT01402089
- Locations
- 🇨🇭
Cantonal Hospital St.Gallen, St.Gallen, Switzerland
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT01396148
- Locations
- 🇺🇸
Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇿Fakultni nemocnice Brno, Brno, Czechia
🇨🇿FN Brno, Brno, Czechia
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 137
- Registration Number
- NCT01396408
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.